APO Research
Talk to an analyst

APO RESEARCH · REPORT

Doxorubicin Hydrochloride

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Doxorubicin Hydrochloride Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025182 pages

Choose your research edition.

Industry ResearchDoxorubicin Hydrochloride Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Doxorubicin Hydrochloride Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Doxorubicin Hydrochloride Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Doxorubicin Hydrochloride Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Doxorubicin Hydrochloride Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Doxorubicin Hydrochloride market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Doxorubicin Hydrochloride is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Doxorubicin Hydrochloride is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Doxorubicin Hydrochloride is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Doxorubicin Hydrochloride is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Doxorubicin Hydrochloride include Medac GmbH, Sun Pharmaceutical, Viatris, Fresenius Kabi, Zhejiang Hisun (HanHui Pharmaceuticals), Pfizer, Shanxi PUDE Pharmaceutical, Shenzhen Main Luck Pharmaceuticals and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Doxorubicin Hydrochloride market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Doxorubicin Hydrochloride and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Doxorubicin Hydrochloride sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Doxorubicin Hydrochloride market size, projected growth trends, production technologies, key applications, and end-use industries.

Doxorubicin Hydrochloride Segment by Company

Medac GmbH

Sun Pharmaceutical

Viatris

Fresenius Kabi

Zhejiang Hisun (HanHui Pharmaceuticals)

Pfizer

Shanxi PUDE Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

Teva

Doxorubicin Hydrochloride Segment by Type

10mg

20mg

50mg

200mg

Others

Doxorubicin Hydrochloride Segment by Application

Malignant Lymphoma

Lung Cancer

Acute Leukemia

Breast Cancer

Others

Doxorubicin Hydrochloride Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Doxorubicin Hydrochloride market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Doxorubicin Hydrochloride and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Doxorubicin Hydrochloride.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Doxorubicin Hydrochloride market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Doxorubicin Hydrochloride manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Doxorubicin Hydrochloride in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Doxorubicin Hydrochloride in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Doxorubicin Hydrochloride Industry Trends Table 2. Doxorubicin Hydrochloride Industry Drivers Table 3. Doxorubicin Hydrochloride Industry Opportunities and Challenges Table 4. Doxorubicin Hydrochloride Industry Restraints Table 5. Global Doxorubicin Hydrochloride Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Doxorubicin Hydrochloride Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Doxorubicin Hydrochloride Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Doxorubicin Hydrochloride Sales Market Share by Manufacturers Table 9. Global Doxorubicin Hydrochloride Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Doxorubicin Hydrochloride Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Doxorubicin Hydrochloride Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Doxorubicin Hydrochloride Manufacturers, Product Type & Application Table 13. Global Doxorubicin Hydrochloride Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Doxorubicin Hydrochloride by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 10mg Table 17. Major Manufacturers of 20mg Table 18. Major Manufacturers of 50mg Table 19. Major Manufacturers of 200mg Table 20. Major Manufacturers of Others Table 21. Global Doxorubicin Hydrochloride Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Doxorubicin Hydrochloride Sales by Type (2021-2026) & (K Units) Table 23. Global Doxorubicin Hydrochloride Sales by Type (2027-2032) & (K Units) Table 24. Global Doxorubicin Hydrochloride Sales Market Share by Type (2021-2026) Table 25. Global Doxorubicin Hydrochloride Sales Market Share by Type (2027-2032) Table 26. Global Doxorubicin Hydrochloride Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Doxorubicin Hydrochloride Revenue by Type (2021-2026) & (K Units) Table 28. Global Doxorubicin Hydrochloride Revenue by Type (2027-2032) & (K Units) Table 29. Global Doxorubicin Hydrochloride Revenue Market Share by Type (2021-2026) Table 30. Global Doxorubicin Hydrochloride Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Malignant Lymphoma Table 32. Major Manufacturers of Lung Cancer Table 33. Major Manufacturers of Acute Leukemia Table 34. Major Manufacturers of Breast Cancer Table 35. Major Manufacturers of Others Table 36. Global Doxorubicin Hydrochloride Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Doxorubicin Hydrochloride Sales by Application (2021-2026) & (K Units) Table 38. Global Doxorubicin Hydrochloride Sales by Application (2027-2032) & (K Units) Table 39. Global Doxorubicin Hydrochloride Sales Market Share by Application (2021-2026) Table 40. Global Doxorubicin Hydrochloride Sales Market Share by Application (2027-2032) Table 41. Global Doxorubicin Hydrochloride Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Doxorubicin Hydrochloride Revenue by Application (2021-2026) & (K Units) Table 43. Global Doxorubicin Hydrochloride Revenue by Application (2027-2032) & (K Units) Table 44. Global Doxorubicin Hydrochloride Revenue Market Share by Application (2021-2026) Table 45. Global Doxorubicin Hydrochloride Revenue Market Share by Application (2027-2032) Table 46. Global Doxorubicin Hydrochloride Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Doxorubicin Hydrochloride Sales by Region (2021-2026) & (K Units) Table 48. Global Doxorubicin Hydrochloride Sales Market Share by Region (2021-2026) Table 49. Global Doxorubicin Hydrochloride Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Doxorubicin Hydrochloride Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Doxorubicin Hydrochloride Sales by Country (2021-2026) & (K Units) Table 53. North America Doxorubicin Hydrochloride Sales by Country (2027-2032) & (K Units) Table 54. Europe Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Doxorubicin Hydrochloride Sales by Country (2021-2026) & (K Units) Table 56. Europe Doxorubicin Hydrochloride Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Doxorubicin Hydrochloride Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Doxorubicin Hydrochloride Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Doxorubicin Hydrochloride Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Doxorubicin Hydrochloride Sales by Country (2027-2032) & (K Units) Table 63. Global Doxorubicin Hydrochloride Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Doxorubicin Hydrochloride Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Doxorubicin Hydrochloride Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Doxorubicin Hydrochloride Revenue Market Share by Region (2021-2026) Table 67. Global Doxorubicin Hydrochloride Revenue Market Share by Region (2027-2032) Table 68. Medac GmbH Company Information Table 69. Medac GmbH Business Overview Table 70. Medac GmbH Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Medac GmbH Doxorubicin Hydrochloride Product Portfolio Table 72. Medac GmbH Recent Development Table 73. Sun Pharmaceutical Company Information Table 74. Sun Pharmaceutical Business Overview Table 75. Sun Pharmaceutical Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sun Pharmaceutical Doxorubicin Hydrochloride Product Portfolio Table 77. Sun Pharmaceutical Recent Development Table 78. Viatris Company Information Table 79. Viatris Business Overview Table 80. Viatris Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Viatris Doxorubicin Hydrochloride Product Portfolio Table 82. Viatris Recent Development Table 83. Fresenius Kabi Company Information Table 84. Fresenius Kabi Business Overview Table 85. Fresenius Kabi Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Fresenius Kabi Doxorubicin Hydrochloride Product Portfolio Table 87. Fresenius Kabi Recent Development Table 88. Zhejiang Hisun (HanHui Pharmaceuticals) Company Information Table 89. Zhejiang Hisun (HanHui Pharmaceuticals) Business Overview Table 90. Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Product Portfolio Table 92. Zhejiang Hisun (HanHui Pharmaceuticals) Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Pfizer Doxorubicin Hydrochloride Product Portfolio Table 97. Pfizer Recent Development Table 98. Shanxi PUDE Pharmaceutical Company Information Table 99. Shanxi PUDE Pharmaceutical Business Overview Table 100. Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Product Portfolio Table 102. Shanxi PUDE Pharmaceutical Recent Development Table 103. Shenzhen Main Luck Pharmaceuticals Company Information Table 104. Shenzhen Main Luck Pharmaceuticals Business Overview Table 105. Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Product Portfolio Table 107. Shenzhen Main Luck Pharmaceuticals Recent Development Table 108. Teva Company Information Table 109. Teva Business Overview Table 110. Teva Doxorubicin Hydrochloride Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Teva Doxorubicin Hydrochloride Product Portfolio Table 112. Teva Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Doxorubicin Hydrochloride Distributors List Table 116. Doxorubicin Hydrochloride Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Doxorubicin Hydrochloride Product Image Figure 2. Global Doxorubicin Hydrochloride Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Doxorubicin Hydrochloride Market Size (2021-2032) & (US$ Million) Figure 4. Global Doxorubicin Hydrochloride Sales (2021-2032) & (K Units) Figure 5. Global Doxorubicin Hydrochloride Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Doxorubicin Hydrochloride Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 10mg Image Figure 9. 20mg Image Figure 10. 50mg Image Figure 11. 200mg Image Figure 12. Others Image Figure 13. Global Doxorubicin Hydrochloride Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Doxorubicin Hydrochloride Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Doxorubicin Hydrochloride Sales Market Share by Type (2021-2032) Figure 16. Global Doxorubicin Hydrochloride Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Doxorubicin Hydrochloride Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Doxorubicin Hydrochloride Revenue Market Share by Type (2021-2032) Figure 19. Malignant Lymphoma Image Figure 20. Lung Cancer Image Figure 21. Acute Leukemia Image Figure 22. Breast Cancer Image Figure 23. Others Image Figure 24. Global Doxorubicin Hydrochloride Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Doxorubicin Hydrochloride Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Doxorubicin Hydrochloride Sales Market Share by Application (2021-2032) Figure 27. Global Doxorubicin Hydrochloride Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Doxorubicin Hydrochloride Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Doxorubicin Hydrochloride Revenue Market Share by Application (2021-2032) Figure 30. North America Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Doxorubicin Hydrochloride Sales Market Share by Country (2021-2032) Figure 32. U.S. Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Doxorubicin Hydrochloride Sales Market Share by Country (2021-2032) Figure 37. Germany Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Doxorubicin Hydrochloride Sales Market Share by Country (2021-2032) Figure 44. China Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Doxorubicin Hydrochloride Sales Market Share by Country (2021-2032) Figure 52. Brazil Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Doxorubicin Hydrochloride Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Doxorubicin Hydrochloride Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Doxorubicin Hydrochloride Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Doxorubicin Hydrochloride Revenue (2021-2032) & (US$ Million) Figure 63. North America Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Doxorubicin Hydrochloride Revenue (2021-2032) & (US$ Million) Figure 65. Europe Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Doxorubicin Hydrochloride Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Doxorubicin Hydrochloride Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Doxorubicin Hydrochloride Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Doxorubicin Hydrochloride Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • 10mg
  • 20mg
  • 50mg
  • 200mg
  • Others
Applications
  • Malignant Lymphoma
  • Lung Cancer
  • Acute Leukemia
  • Breast Cancer
  • Others
Companies covered
  • Medac GmbH
  • Sun Pharmaceutical
  • Viatris
  • Fresenius Kabi
  • Zhejiang Hisun (HanHui Pharmaceuticals)
  • Pfizer
  • Shanxi PUDE Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Doxorubicin Hydrochloride Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Doxorubicin Hydrochloride Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Doxorubicin Hydrochloride Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Doxorubicin Hydrochloride Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Doxorubicin Hydrochloride Market Dynamics
  1. 2.1 Doxorubicin Hydrochloride Industry Trends
  2. 2.2 Doxorubicin Hydrochloride Industry Drivers
  3. 2.3 Doxorubicin Hydrochloride Industry Opportunities and Challenges
  4. 2.4 Doxorubicin Hydrochloride Industry Restraints
3 Doxorubicin Hydrochloride Market by Manufacturers
  1. 3.1 Global Doxorubicin Hydrochloride Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Doxorubicin Hydrochloride Sales by Manufacturers (2021-2026)
  3. 3.3 Global Doxorubicin Hydrochloride Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Doxorubicin Hydrochloride Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Doxorubicin Hydrochloride Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Doxorubicin Hydrochloride Manufacturers, Product Type & Application
  7. 3.7 Global Doxorubicin Hydrochloride Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Doxorubicin Hydrochloride Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Doxorubicin Hydrochloride Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Doxorubicin Hydrochloride Tier 1, Tier 2, and Tier 3
4 Doxorubicin Hydrochloride Market by Type
  1. 4.1 Doxorubicin Hydrochloride Type Introduction
  2. 4.1.1 10mg
  3. 4.1.2 20mg
  4. 4.1.3 50mg
  5. 4.1.4 200mg
  6. 4.1.5 Others
  7. 4.2 Global Doxorubicin Hydrochloride Sales by Type
  8. 4.2.1 Global Doxorubicin Hydrochloride Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Doxorubicin Hydrochloride Sales by Type (2021-2032)
  10. 4.2.3 Global Doxorubicin Hydrochloride Sales Market Share by Type (2021-2032)
  11. 4.3 Global Doxorubicin Hydrochloride Revenue by Type
  12. 4.3.1 Global Doxorubicin Hydrochloride Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Doxorubicin Hydrochloride Revenue by Type (2021-2032)
  14. 4.3.3 Global Doxorubicin Hydrochloride Revenue Market Share by Type (2021-2032)
5 Doxorubicin Hydrochloride Market by Application
  1. 5.1 Doxorubicin Hydrochloride Application Introduction
  2. 5.1.1 Malignant Lymphoma
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Acute Leukemia
  5. 5.1.4 Breast Cancer
  6. 5.1.5 Others
  7. 5.2 Global Doxorubicin Hydrochloride Sales by Application
  8. 5.2.1 Global Doxorubicin Hydrochloride Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Doxorubicin Hydrochloride Sales by Application (2021-2032)
  10. 5.2.3 Global Doxorubicin Hydrochloride Sales Market Share by Application (2021-2032)
  11. 5.3 Global Doxorubicin Hydrochloride Revenue by Application
  12. 5.3.1 Global Doxorubicin Hydrochloride Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Doxorubicin Hydrochloride Revenue by Application (2021-2032)
  14. 5.3.3 Global Doxorubicin Hydrochloride Revenue Market Share by Application (2021-2032)
6 Global Doxorubicin Hydrochloride Sales by Region
  1. 6.1 Global Doxorubicin Hydrochloride Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Doxorubicin Hydrochloride Sales by Region (2021-2032)
  3. 6.2.1 Global Doxorubicin Hydrochloride Sales by Region (2021-2026)
  4. 6.2.2 Global Doxorubicin Hydrochloride Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Doxorubicin Hydrochloride Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Doxorubicin Hydrochloride Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Doxorubicin Hydrochloride Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Doxorubicin Hydrochloride Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Doxorubicin Hydrochloride Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Doxorubicin Hydrochloride Revenue by Region
  1. 7.1 Global Doxorubicin Hydrochloride Revenue by Region
  2. 7.1.1 Global Doxorubicin Hydrochloride Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Doxorubicin Hydrochloride Revenue by Region (2021-2026)
  4. 7.1.3 Global Doxorubicin Hydrochloride Revenue by Region (2027-2032)
  5. 7.1.4 Global Doxorubicin Hydrochloride Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Doxorubicin Hydrochloride Revenue (2021-2032)
  8. 7.2.2 North America Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Doxorubicin Hydrochloride Revenue (2021-2032)
  11. 7.3.2 Europe Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Doxorubicin Hydrochloride Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Doxorubicin Hydrochloride Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Doxorubicin Hydrochloride Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Medac GmbH
  2. 8.1.1 Medac GmbH Company Information
  3. 8.1.2 Medac GmbH Business Overview
  4. 8.1.3 Medac GmbH Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Medac GmbH Doxorubicin Hydrochloride Product Portfolio
  6. 8.1.5 Medac GmbH Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Doxorubicin Hydrochloride Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Doxorubicin Hydrochloride Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 Fresenius Kabi
  20. 8.4.1 Fresenius Kabi Company Information
  21. 8.4.2 Fresenius Kabi Business Overview
  22. 8.4.3 Fresenius Kabi Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fresenius Kabi Doxorubicin Hydrochloride Product Portfolio
  24. 8.4.5 Fresenius Kabi Recent Developments
  25. 8.5 Zhejiang Hisun (HanHui Pharmaceuticals)
  26. 8.5.1 Zhejiang Hisun (HanHui Pharmaceuticals) Company Information
  27. 8.5.2 Zhejiang Hisun (HanHui Pharmaceuticals) Business Overview
  28. 8.5.3 Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Product Portfolio
  30. 8.5.5 Zhejiang Hisun (HanHui Pharmaceuticals) Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Doxorubicin Hydrochloride Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Shanxi PUDE Pharmaceutical
  38. 8.7.1 Shanxi PUDE Pharmaceutical Company Information
  39. 8.7.2 Shanxi PUDE Pharmaceutical Business Overview
  40. 8.7.3 Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Product Portfolio
  42. 8.7.5 Shanxi PUDE Pharmaceutical Recent Developments
  43. 8.8 Shenzhen Main Luck Pharmaceuticals
  44. 8.8.1 Shenzhen Main Luck Pharmaceuticals Company Information
  45. 8.8.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  46. 8.8.3 Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Product Portfolio
  48. 8.8.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Doxorubicin Hydrochloride Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Doxorubicin Hydrochloride Product Portfolio
  54. 8.9.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Doxorubicin Hydrochloride Value Chain Analysis
  2. 9.1.1 Doxorubicin Hydrochloride Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Doxorubicin Hydrochloride Production Mode & Process
  6. 9.2 Doxorubicin Hydrochloride Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Doxorubicin Hydrochloride Distributors
  9. 9.2.3 Doxorubicin Hydrochloride Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst